https://www.pharmaradar360.com/article/4eb5d61daf8b5c1ePharmaRadar360en2026-04-20T11:21:35.000ZFernando Tauber Presidente de la UNLPhttps://www.pharmaradar360.com/article/84e5256e6beb4e0dPharmaRadar360en2026-04-20T10:57:44.000Z“Skin patch helped me spot lung rejection” says beneficiaryhttps://www.pharmaradar360.com/article/988bc66ff620e495PharmaRadar360en2026-04-20T10:48:00.000ZFDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/10068426bb62b7f9PharmaRadar360en2026-04-20T10:46:34.000ZNovo Nordisk’s sickle cell therapy hits in Phase 3, but data lag expectationshttps://www.pharmaradar360.com/article/0bd2edd1d38e5c5cPharmaRadar360en2026-04-20T10:44:47.000ZNCT/UCC- Patiententag 2026https://www.pharmaradar360.com/article/8f645f4436f843ecPharmaRadar360en2026-04-20T10:16:55.000ZACI’s 2nd Annual Summit on GLP-1 Law & Policyhttps://www.pharmaradar360.com/article/7376807384c7a528PharmaRadar360en2026-04-20T10:08:00.000ZHelsinki Legal History Series: Karolina Stenlundhttps://www.pharmaradar360.com/article/06b4f59dcec26115PharmaRadar360en2026-04-20T10:00:57.000ZNHS App ‘not improving patients’ views on NHS admin’https://www.pharmaradar360.com/article/5375f1519d2c94a8PharmaRadar360en2026-04-20T10:00:00.000ZAddressing Regulatory Issues and the Biosimilar Void: Q&A with Thomas Newcomerhttps://www.pharmaradar360.com/article/85a17d836a0a7af0PharmaRadar360en2026-04-20T09:10:28.000ZHIKET session at the 5th ACCC Impact Weekhttps://www.pharmaradar360.com/article/9389f15ea2c67e21PharmaRadar360en2026-04-20T08:57:49.000ZUpdate after flooding on Stellenbosch campushttps://www.pharmaradar360.com/article/94db5ab0d2be6cfcPharmaRadar360en2026-04-20T08:36:41.000ZLa UE abre consulta pública sobre la propuesta de restricción de las PFAShttps://www.pharmaradar360.com/article/bec2fd01e5c09043PharmaRadar360en2026-04-20T08:30:00.000ZNotice Regarding Determination of Issue Price, Selling Price and Other Mattershttps://www.pharmaradar360.com/article/0a01ac1b6ada1a1dPharmaRadar360en2026-04-20T08:29:08.000ZSuomen Tiedeseuran suuri palkinto 2026 professori Tuomas Heikkilällehttps://www.pharmaradar360.com/article/3f2bb1b16ba551efPharmaRadar360en2026-04-20T08:15:02.000ZESR iGuide goes live at Hospital Universitari del Consorci Sanitari de Terrassa, enhancing Imaging Appropriatenesshttps://www.pharmaradar360.com/article/a9fe64707b66946ePharmaRadar360en2026-04-20T08:01:54.000ZHelsus Brown Bag lunch talk, by Alizée Ville, April 23rd 2026https://www.pharmaradar360.com/article/ce1518081e5b14e3PharmaRadar360en2026-04-20T07:58:53.000ZNew study shows editing grapevine DNA could boost resistance to disease and droughthttps://www.pharmaradar360.com/article/ccc9f5cf5a389c0bPharmaRadar360en2026-04-20T07:21:06.000ZGranuLean: high-quality granulation on a compact footprinthttps://www.pharmaradar360.com/article/a1df3ba640f028c6PharmaRadar360en2026-04-20T07:00:00.000ZStudy suggests link between prenatal exposure to certain medications and increased autism riskhttps://www.pharmaradar360.com/article/e37b4cfc9776282bPharmaRadar360en2026-04-20T07:00:00.000ZHow Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordabilityhttps://www.pharmaradar360.com/article/ebde7386bb742f1bPharmaRadar360en2026-04-20T07:00:00.000ZImmunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Updatehttps://www.pharmaradar360.com/article/f6b177cc832337afPharmaRadar360en2026-04-20T07:00:00.000ZWhen the System Is the Treatment: Rethinking Nonpharmacologic Breakthroughs in Oncologyhttps://www.pharmaradar360.com/article/d939018acfef836cPharmaRadar360en2026-04-20T07:00:00.000ZVIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancerhttps://www.pharmaradar360.com/article/65e2428ed9fa0e65PharmaRadar360en2026-04-20T07:00:00.000ZBridging the Gap: What We Can Learn From LEAP-010 in Recurrent/Metastatic Head and Neck Cancerhttps://www.pharmaradar360.com/article/9549183bb21e8a73PharmaRadar360en2026-04-20T07:00:00.000ZReply to: “Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases,” “Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials,” and “Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases”https://www.pharmaradar360.com/article/cbd5466887875f7dPharmaRadar360en2026-04-20T07:00:00.000ZGood Oncologist: Doctoring Lessons From the Art of Oncologyhttps://www.pharmaradar360.com/article/595da72bb40e50bfPharmaRadar360en2026-04-20T07:00:00.000ZTarget Trial Emulation for Regulatory and Clinical Decision Making in Cancerhttps://www.pharmaradar360.com/article/67d75d2ad8ba904aPharmaRadar360en2026-04-20T07:00:00.000ZExpanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastaseshttps://www.pharmaradar360.com/article/c623bb478afc735bPharmaRadar360en2026-04-20T07:00:00.000ZCALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancerhttps://www.pharmaradar360.com/article/eadc88d854c94be2PharmaRadar360en2026-04-20T07:00:00.000ZRadiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trialshttps://www.pharmaradar360.com/article/d327b09f29b934d9PharmaRadar360en2026-04-20T07:00:00.000ZLimitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastaseshttps://www.pharmaradar360.com/article/88723aa4bbe5ada1PharmaRadar360en2026-04-20T07:00:00.000ZNivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trialhttps://www.pharmaradar360.com/article/3d61e20d24ffd678PharmaRadar360en2026-04-20T07:00:00.000ZEfficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)https://www.pharmaradar360.com/article/a6ac10042ad4f60fPharmaRadar360en2026-04-20T07:00:00.000ZFinancial Hardship Before Diagnosis: Influence on Late-Stage Cancer Presentation and the Role of Screeninghttps://www.pharmaradar360.com/article/8abb6594281a84bfPharmaRadar360en2026-04-20T07:00:00.000ZPembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Studyhttps://www.pharmaradar360.com/article/cd37aa9918e50d5bPharmaRadar360en2026-04-20T06:58:00.000ZUNMC Better Processes Initiative getting underwayhttps://www.pharmaradar360.com/article/564bcf6acc39ddf8PharmaRadar360en2026-04-20T06:56:00.000ZUNMC, Nebraska Medicine host For the Greater Good this weekhttps://www.pharmaradar360.com/article/7f658264fd0f23daPharmaRadar360en2026-04-20T06:54:00.000ZNew intranet design, other digital updateshttps://www.pharmaradar360.com/article/038850602c8b5357PharmaRadar360en2026-04-20T06:30:30.000ZTees, Esk and Wear Valleys signs contract to deploy Access EPRhttps://www.pharmaradar360.com/article/0dd67061d0314743PharmaRadar360en2026-04-20T06:28:09.000ZUnga idéer blev verklighet i Bengtsfors, Lysekil och Munkedalhttps://www.pharmaradar360.com/article/50b74eb9368ea262PharmaRadar360en2026-04-20T06:02:24.000ZResearch position at Suzuki Lab, Center for Cancer Immunotherapy and Immunobiology (CCII), Kyoto Universityhttps://www.pharmaradar360.com/article/85e90d299122ce80PharmaRadar360en2026-04-20T06:00:00.000ZVillage Alzheimer : un accompagnement qui améliore le devenir médical des résidentshttps://www.pharmaradar360.com/article/576e8b561dfef766PharmaRadar360en2026-04-20T05:53:00.000ZAgenus focuses on survival data as 0% response rate triggers primary misshttps://www.pharmaradar360.com/article/92f65b51bf64ad96PharmaRadar360en2026-04-20T05:44:00.000Z#EVENTO. [20.04] Giornata nazionale per la donazione di organi e tessuti: nel ricordo dei donatori del Policlinico di Milanohttps://www.pharmaradar360.com/article/4420bfd9dd6a1c15PharmaRadar360en2026-04-20T04:53:00.000ZAstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD winhttps://www.pharmaradar360.com/article/9076c6062bb963c4PharmaRadar360en2026-04-20T04:42:00.000ZTrump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcasterhttps://www.pharmaradar360.com/article/ccae4d1ce95d2a20PharmaRadar360en2026-04-20T04:10:00.000ZOdyssey charts fresh voyage to public markets after abandoning IPO plans last yearhttps://www.pharmaradar360.com/article/bad301847a026aebPharmaRadar360en2026-04-20T03:00:00.000Z[KOKUSAI]A new page for the Regulatory Symposia has been launched.https://www.pharmaradar360.com/article/f7696a4e9bd22d6aPharmaRadar360en2026-04-20T02:23:50.000Z#AACR26: KRAS drugmakers take another, better swing at lung cancerhttps://www.pharmaradar360.com/article/ed0dee9ceb8d2c64PharmaRadar360en2026-04-20T02:00:00.000ZAgenda for May 2026 Pharmacology and Therapeutics advisory committee (PTAC) meetinghttps://www.pharmaradar360.com/article/dacc27d442d3ba67PharmaRadar360en2026-04-20T01:50:11.000ZFM DTS融合セミナー スタンフォード大学/MedVenture Partners, Inc 池野 文昭先生講演会開催のお知らせ（5/20開催）https://www.pharmaradar360.com/article/d27c42927f87891fPharmaRadar360en2026-04-20T01:45:33.000ZUCB plots epilepsy expansion with $650M Neurona cell therapy acquisitionhttps://www.pharmaradar360.com/article/8de956189b755751PharmaRadar360en2026-04-20T01:00:00.000ZScleral lens “Time XL” acquires approval in China - New option for patients with irregular cornea available in the Chinese market -https://www.pharmaradar360.com/article/c138d1dc858743edPharmaRadar360en2026-04-20T00:54:19.000ZOdyssey Therapeutics will try again to IPO, this time in a warmer markethttps://www.pharmaradar360.com/article/90b0d7bb8c3058dbPharmaRadar360en2026-04-20T00:00:00.000ZOtsuka Foods to Revise Prices of Some Products New Prices to Take Effect with Deliveries as of June 1, 2026https://www.pharmaradar360.com/article/7e81346de3d7b2d4PharmaRadar360en2026-04-20T00:00:00.000ZComprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposinghttps://www.pharmaradar360.com/article/2545eec028367987PharmaRadar360en2026-04-20T00:00:00.000ZSafety considerations for cereblon-recruiting targeted protein degradershttps://www.pharmaradar360.com/article/d8ce2dce5089b37bPharmaRadar360en2026-04-20T00:00:00.000ZTarget identification and assessment in the era of AIhttps://www.pharmaradar360.com/article/dd7956c0b50f8f77PharmaRadar360en2026-04-20T00:00:00.000ZThrilling, frivolous, a waste: not everyone’s happy about the Artemis II Moon missionhttps://www.pharmaradar360.com/article/3f7225109ad84fe4PharmaRadar360en2026-04-20T00:00:00.000ZHow hidden contributions power modern researchhttps://www.pharmaradar360.com/article/499bcea5e2f44a14PharmaRadar360en2026-04-20T00:00:00.000ZWhat does the future hold for the thawing Arctic?https://www.pharmaradar360.com/article/78ff560619b68c3fPharmaRadar360en2026-04-20T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/36d3deec392bece2PharmaRadar360en2026-04-20T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/a3828d1cacb4af4aPharmaRadar360en2026-04-20T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/443432cc2b56d4cbPharmaRadar360en2026-04-20T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/8a50fbf13520dc36PharmaRadar360en2026-04-20T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/9f2d65c16f31f8c1PharmaRadar360en2026-04-20T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/713bf924162044cfPharmaRadar360en2026-04-20T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/e8583d73d467038dPharmaRadar360en2026-04-20T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/d9eb24b6bbe9bbe8PharmaRadar360en2026-04-20T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/dbf6019a0956d7edPharmaRadar360en2026-04-20T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/ca41fb565fe22c73PharmaRadar360en2026-04-20T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/2e0e895b547c83c1PharmaRadar360en2026-04-20T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/83389ea859e996e9PharmaRadar360en2026-04-20T00:00:00.000Z6203https://www.pharmaradar360.com/article/11992f652c42309bPharmaRadar360en2026-04-20T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/243146afe3d2a299PharmaRadar360en2026-04-20T00:00:00.000ZNews Published on 2026/04/20 タグ University News Kyoto University releases "Creating our future together: KyotoU Future Commons"https://www.pharmaradar360.com/article/abd1491c654f1cdaPharmaRadar360en2026-04-20T00:00:00.000ZKI inviger nytt centrum – ska lyfta AI från projekt till praktikhttps://www.pharmaradar360.com/article/75d104503f12dbe5PharmaRadar360en2026-04-20T00:00:00.000ZUnited Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026https://www.pharmaradar360.com/article/a9c3a20076f4f275PharmaRadar360en2026-04-19T23:01:01.000ZClinical investigations for medical deviceshttps://www.pharmaradar360.com/article/d883a6dc11a21486PharmaRadar360en2026-04-19T22:00:00.000ZEinladung zu Umfrage zum Ausbruchsmanagement in Gemeinschaftsunterkünften für Leitlinienentwicklunghttps://www.pharmaradar360.com/article/95f66a914c44313ePharmaRadar360en2026-04-19T21:15:00.000ZDOJ seeks immediate asset freeze, receivership against telehealth company Zealthyhttps://www.pharmaradar360.com/article/190158aada0fccfdPharmaRadar360en2026-04-19T19:56:46.000ZStockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analystshttps://www.pharmaradar360.com/article/9324f9009a225dbaPharmaRadar360en2026-04-19T14:30:00.000ZAAN 2026: From Migraines to Alzheimer, How the Menopausal Transition Affects Neurological Risk in Womenhttps://www.pharmaradar360.com/article/28fbfbfd5aa2f142PharmaRadar360en2026-04-19T14:00:00.000ZAAN 2026: Sex and Gender Gaps in TBI Care, What Pharmacists and Clinicians Need to Knowhttps://www.pharmaradar360.com/article/164ab4bd7d186139PharmaRadar360en2026-04-19T13:05:54.000ZLive Updates From the AACR Annual Meeting 2026: Sunday, April 19https://www.pharmaradar360.com/article/1ec555743ee37e0dPharmaRadar360en2026-04-19T12:42:00.000ZFDA celebrates progress to end animal testing but experts warn there’s still a long way to gohttps://www.pharmaradar360.com/article/772308c34a2e469fPharmaRadar360en2026-04-19T12:30:00.000ZCelebrating National Volunteer Week & the International Year of Volunteershttps://www.pharmaradar360.com/article/a97eb6c6b7adfc20PharmaRadar360en2026-04-19T10:04:30.000ZUpdate for Jitendra Narayanhttps://www.pharmaradar360.com/article/07bbfe5feea733eePharmaRadar360en2026-04-19T10:04:30.000ZUpdate for Rishabhhttps://www.pharmaradar360.com/article/703e139dc9b35d0fPharmaRadar360en2026-04-19T09:58:00.000ZAACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugshttps://www.pharmaradar360.com/article/ce8456846a2ff1f3PharmaRadar360en2026-04-19T06:14:12.000ZPFA Under Deep Sedation and Non‐Invasive Monitoring in Atrial Fibrillation Patients With Obstructive Sleep Apneahttps://www.pharmaradar360.com/article/8090e7a59c5579dfPharmaRadar360en2026-04-19T06:10:14.000ZMultipoint Pacing Versus Cardiac Resynchronization Therapy in Heart Failure: A Systematic Review and Meta‐Analysishttps://www.pharmaradar360.com/article/0c98088ffca04367PharmaRadar360en2026-04-19T06:03:48.000ZAtrial Reverse Remodeling by Bachmann's Bundle Pacing With Improved Interatrial Dyssynchrony: Case Serieshttps://www.pharmaradar360.com/article/3725f296215d1353PharmaRadar360en2026-04-19T05:59:53.000ZStrength‐Duration Characterisation of Subcutaneous Pacing: A Preclinical Studyhttps://www.pharmaradar360.com/article/393f900566cc70d1PharmaRadar360en2026-04-19T03:45:14.000ZScientists say this type of olive oil could boost brain powerhttps://www.pharmaradar360.com/article/324c5a93ab7f9352PharmaRadar360en2026-04-19T03:34:30.000ZEVs can support home energy billshttps://www.pharmaradar360.com/article/079c310c7c4f9dc6PharmaRadar360en2026-04-19T03:04:33.000Z10x Genomics Unveils Atera Spatial Platform at AACR Meetinghttps://www.pharmaradar360.com/article/162f9b1b107013acPharmaRadar360en2026-04-19T00:25:24.000ZUpdate for Jitendra Narayanhttps://www.pharmaradar360.com/article/b97e70d4c4684c90PharmaRadar360en2026-04-18T23:13:44.000ZThree gene therapy pioneers just won the Breakthrough Prize. This is their storyhttps://www.pharmaradar360.com/article/a075b48f50136515PharmaRadar360en2026-04-18T20:30:00.000ZZelicapavir Demonstrates High Clinical and Functional Barrier Against Antiviral Resistance: Results from a Randomized Double-Blind Placebo-Controlled Pediatric RSV Antiviral Clinical Trialhttps://www.pharmaradar360.com/article/292f40a55c3fcbdaPharmaRadar360en2026-04-18T20:29:00.000ZZelicapavir Decreases Symptom Duration, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of High-Risk Adults with RSVhttps://www.pharmaradar360.com/article/0294d9e731c9c3fdPharmaRadar360en2026-04-18T16:29:00.000ZPotent STAT6 Inhibitor EPS-3903 Has Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition with Once-Daily Oral Dosing in Humans